P626: FUNCTIONAL SCREENING OF PI3K INHIBITORS STRATIFIES RESPONDERS TO IDELALISIB AND INDICATES DRUG CLASS ACTIVITY IN IDELALISIB-REFRACTORY CLL

• S. Skånland,
• Y. Yanping,
• P. Athanasiadis,
• L. Karlsen,
• A. Urban,
• I. Murali,
• S. Fernandes,
• A. Hilli,
• K. Taskén,
• F. Bertoni,
• A. Mato,
• E. Normant,
• J. Brown,
• G. Tjønnfjord,
• T. Aittokallio

Affiliations

S. Skånland

1 Oslo University Hospital, Oslo, Norway

Y. Yanping

1 Oslo University Hospital, Oslo, Norway

P. Athanasiadis

1 Oslo University Hospital, Oslo, Norway

L. Karlsen

1 Oslo University Hospital, Oslo, Norway

A. Urban

1 Oslo University Hospital, Oslo, Norway

I. Murali

2 Dana-Farber Cancer Institute, Boston, United States of America

S. Fernandes

2 Dana-Farber Cancer Institute, Boston, United States of America

A. Hilli

3 Diakonhjemmet Hospital, Oslo, Norway

K. Taskén

1 Oslo University Hospital, Oslo, Norway

F. Bertoni

4 Università della svizzera italiana, Bellinzona, Switzerland

A. Mato

5 Memorial Sloan Kettering Cancer Center

E. Normant

6 TG Therapeutics, New York, United States of America

J. Brown

2 Dana-Farber Cancer Institute, Boston, United States of America

G. Tjønnfjord

1 Oslo University Hospital, Oslo, Norway

T. Aittokallio

1 Oslo University Hospital, Oslo, Norway